Biotech News

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc (VERU)Veru IncClinical readout

VERU (VERU) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is veru.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VERUVeru Inc2026-11-17 13:30 EST

Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

BNTXBioNTech2026-10-22 10:45 EST

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

PRLDPrelude Therapeutics2026-10-13 11:01 EST

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

VERUVeru Inc2026-11-09 13:30 EST

Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026

BNTXBioNTech2026-10-13 10:45 EST

BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer

ERASErasca2026-11-04 13:30 EST

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

MGNXMacroGenics2026-10-23 13:15 EST

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

IMCRImmunocore Holdings plc2026-10-15 11:00 EST

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Veru Inc

Cardiometabolic and Inflammation Company Veru develops late-stage small molecules for cardiometabolic and inflammatory diseases. Enobosarm Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with...

Recent company news

Stock data

Close
2.11 USD
Market cap
37.72M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States